EZH2 and neoplasm: Pharmacologic inhibition of EZH2 has demonstrated anti-tumor efficacy in preclinical models, including cellular growth arrest, induction of apoptosis, and neuronal differentiation, as well as delayed tumor progression in murine xenografts (12).